-
#2019nCoV uses#ACE2 and#TMPRSS2 to enter cells. TMPRSS2 putative target for#therapy.#SARS-CoV antibodies partially neutralized#2019nCoV. Great and fast work by our colleagues at#DPZ#ChariteVirology @ChariteBerlin https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1 … -
Where do human coronaviruses come from? Great review of my colleagues at
#CharitéVirology@vmcorman https://www.sciencedirect.com/science/article/pii/S0065352718300010?via%3Dihub …pic.twitter.com/ubx5CKnslw
-
We just put the sequence of the first German
#nCoV2019 case online. Available via GISAID.#SARS#WuhanPneumonia#ChariteVirology@ChariteBerlin@BundeswehrInfo http://www.gisaid.org -
Insights from the frontline of testing for
#nCoV2019 in Germany:#FactsNoFear#SARS#Coronavirus#ChariteVirology@ChariteBerlinpic.twitter.com/5m2cRPf3vi
-
Similar to
#nCoV2019, the#MERS#coronavirus can cause severe#pneumonia. Virologists from#CharitéBerlin identified a cellular recycling process known as#autophagy as a potential target for treatment. https://bit.ly/2GA2gcW#ChariteVirology@DZIF_@NatureCommspic.twitter.com/BiCTDdKpDI
-
-
I wish diagnostics is: thinking about cases, working in a lab, and setting up tests. In real life it's sample logistics and explaining people how to pack and label shipments, that never show up in time.
#SARS#WuhanPneumonia#ChariteVirology#Coronavirus -
Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome (
#MERS)#coronavirus. Congrats to my colleagues at#DPZ; a collaboration with#ChariteVirology#DZIFhttps://www.tandfonline.com/doi/full/10.1080/22221751.2020.1713705 … -
Pre-emptive genomic surveillance of emerging ebolaviruses.
@Eurosurveillanc@CarloFischer10#DrexlerLab#ChariteVirology@Charite https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.3.1900765 … -
Weil Coronaviren z.Z. in aller Munde sind, hier unter
#CoronaInfo etwas Hintergrund zu dieser Virusfamilie. Coronaviren gibt es auch bei uns! Wir (@MDC_Berlin) machen mit#CharitéVirology an Einzelzellsequenzierung von NL63-infizierten Zellen. (1/2)Prikaži ovu nit -
Actually, most of the lab work at
#ChariteVirology is done by the great team. Many smart people who support each other. Thank you!Prikaži ovu nit -
Led by Prof. Dr. Christian Drosten, researchers from
#CharitéBerlin have developed the first diagnostic test for the novel#coronavirus in China. Their assay protocol has now been published by@WHO. https://bit.ly/30pjbIi#nCoV2019#ChariteVirology@DZIF#WuhanPneumoniapic.twitter.com/GuGDKKe3mH
-
Ein Team um Prof. Christian Drosten von
#CharitéBerlin hat das erste Nachweisverfahren für das derzeit in China kursierende#Coronavirus entwickelt. Das Testprotokoll wurde nun von der@WHO veröffentlicht. https://bit.ly/2u94Tzp#nCoV2019#ChariteVirology#WuhanPneumonia@DZIFpic.twitter.com/KNVcw2270k
-
First validated diagnostic real-time PCR for the detection of
#Wuhan#coronavirus made available by our institute and recommended by#WHO#ChariteVirology#nCoV-2019 @vmcorman @ChariteBerlinhttps://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus … -
Our
#review might help if you decide to set up#serological assays for#Wuhan#Coronavirus#ChariteVirology Serological assays for emerging coronaviruses: challenges and pitfalls. - PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/24670324/ … -
Yesterday, I cycled along the former death strip and the former Berlin Wall. Today I'm heading off to
#EVDlabnet meeting in Greece. Looking forward to meet people across Europe to improve virus diagnostics within the EU. Walls/borders won't help.@ECDC_EU#ChariteVirology -
#agdrexler#charitevirology Prof Felix Drexler talking about cross protection of congenital zika syndrome by dengue infection@CarloFischer10https://twitter.com/ZIKAlliance/status/1187679800380608513 …
-
Day 2 of
#Zoonoses2019:@CarloFischer10 from#CharitéVirology is one of the first presenters in the Epidemiology and Ecology session, sharing his data on crossprotection of Dengue virus infection against Congenital Zika Syndrome. pic.twitter.com/NtUCcJmhSd
Prikaži ovu nit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.